In a patient with a history of antidepressant‑induced mania on escitalopram, one year of suicidality, and prior treatment failures with lamotrigine and clonidine, who screened negative on the Mood Disorder Questionnaire (MDQ) and clinical exam for bipolar disorder, should I add mirtazapine at this time?

Do Not Add Mirtazapine at This Time

Given this patient's documented history of antidepressant-induced mania on escitalopram, adding mirtazapine now—despite negative MDQ and clinical screening—poses an unacceptable risk of precipitating another manic episode and potentially worsening suicidality. The patient's prior treatment response pattern strongly suggests underlying bipolar diathesis, regardless of current screening results.

Critical Clinical Context

This patient has already demonstrated antidepressant-induced mania with escitalopram 1, which according to DSM-IV-TR criteria represents substance-induced mania but may also indicate unmasking of bipolar disorder 2. The negative MDQ and clinical exam do not rule out bipolar disorder—they simply indicate the patient is not currently manic and may not recall or recognize past hypomanic symptoms.

Why Antidepressant Monotherapy Is Contraindicated

Antidepressants used without mood stabilizers carry substantial risk in patients with any bipolar features:

• Guidelines explicitly state that antidepressants may be useful adjuncts for depression only as long as the patient is also taking at least one mood stabilizer 2
• Antidepressants can destabilize mood or incite manic episodes, with this risk being particularly high in patients who have previously experienced antidepressant-induced mania 2, 3
• WHO guidelines recommend that antidepressant medicines, always in combination with a mood stabilizer (lithium or valproate), may be considered for bipolar depression 4

The Suicidality Concern

The patient's one-year history of suicidality adds another layer of complexity:

• Mirtazapine carries FDA black box warnings about increased risk of suicidal thoughts or actions in young adults, especially within the first few months of treatment 5
• Antidepressants are associated with increased risk for nonfatal suicide attempts compared to placebo 6
• In bipolar patients, antidepressant-induced mood destabilization (including mixed states) is strongly associated with increased suicidality 7, 8

The Correct Treatment Approach

Before considering any antidepressant, this patient requires:

1. Initiation of a mood stabilizer first: Lithium or valproate should be started as primary treatment 2, 4, 2

   • Lithium has specific anti-suicidal properties that are particularly relevant given this patient's history 7, 9
   • Lithium reduces the frequency of antidepressant-induced mood switches 3

2. Re-evaluation after mood stabilizer reaches therapeutic levels: Wait 2-4 weeks to assess response

3. Only then consider antidepressant augmentation if depressive symptoms persist, and only with:

   • Continued mood stabilizer coverage
   • Close monitoring for mood destabilization
   • Preference for SSRIs over tricyclics if antidepressant is needed 4
   • Awareness that mirtazapine specifically can cause activation of mania/hypomania 5

Why Lamotrigine Failure Doesn't Change This

The patient's prior lamotrigine failure doesn't justify bypassing mood stabilizer coverage. Lamotrigine is primarily effective for bipolar depression maintenance rather than acute treatment 2. Lithium or valproate remain first-line options that haven't been tried in this patient 2, 4, 2.

Common Pitfalls to Avoid

• Don't rely solely on negative screening tools: The MDQ has limited sensitivity, and patients often don't recognize or report hypomanic symptoms
• Don't assume substance-induced mania is categorically different from bipolar disorder: Antidepressant-induced mania may represent unmasking of underlying bipolar vulnerability 2, 1
• Don't underestimate the risk of rapid cycling: Antidepressants without mood stabilizers can induce rapid cycling, particularly in younger patients 10
• Don't forget that mirtazapine is still an antidepressant: Despite its different mechanism, it carries similar risks for mood destabilization in bipolar-spectrum patients 5

The evidence is clear: establish mood stabilization first, then reassess the need for antidepressant augmentation under appropriate coverage.